Preview

Osteoporosis and Bone Diseases

Advanced search

IZMENENIYa MINERAL'NOY PLOTNOSTI KOSTNOY TKANI U BOL'NYKh ANKILOZIRUYuShchIM SPONDILOARTRITOM

https://doi.org/10.14341/osteo2011314-18

Abstract

Objective. To determine a bone mineral density (BMD) changes in patients with ankylosing spondylitis (AS) depending on demographical data, clinical and laboratory findings. Materials and methods. 42 patients (male - 36 (85,7%), female - 6 (14,3%), 21 to 47 years of age, mean age 33,2±8,4, mean disease duration 7,8±5,9 years) with proven diagnosis of AS were included in the study performed at the Centre of osteoporosis treatment and prevention. All patients were HLA-B27 positive, 23 (54,8%) had peripheral arthritis. Evaluation included back pain assessment with VAS scale, morning stiffness duration assessment, modified Schober’s test, limitation of chest expansion assessment, calculation of BASDAI, BASFI and ASDAS-CRP scores, ESR and CRP levels. To evaluate BMD all patient underwent dual-emission X-ray absorptiometry (DXA) at lumbar spine (L1-L4) and hip neck. Results. Among male patients normal BMD was found in 6 (16,7%) patients, 19 (52,8%) had osteopenia, 11 (30,5%) -osteoporosis. Among male patients normal BMD was found in 1 (16,7%) patients, 1 (16,7%) had osteopenia, 4 (66,6°%) — osteoporosis. BMD at the lumbar spine in male patients was significantly higher compared to females (p<0,05). Patients with high disease activity and peripheral arthritis had significantly lower BMD at lumbar spine. Patients with osteoporosis and osteopenia had higher pain score on VAS compared to patients with normal BMD. We observed an association between BMD and duration of AS, Schober’s test results, disease activity and CRP. Conclusion. High clinical activity, presence of peripheral arthritis, significant changes in spinal movement were found to be predictors of BMD decrease in patients with AS. Patients with AS and osteopenia had more pronounced pain syndrome.

About the Authors

L. I. MYaSOUTOVA

assistent kafedry gospital'noy terapii


S. A. LAPShINA

k.m.n., assistent kafedry gospital'noy terapii


I. G. SALIKhOV

zav. kafedroy gospital'noy terapii, professor, d.m.n., chlen-korrespondent AN RT, glavnyy revmatolog


A. G. VASIL'EV

aspirant kafedry gospital'noy terapii


References

1. Braun, J. Building consensus on nomenclature and disease classification for ankylosing spondylitis: results and discussion of a questionnaire prepared for the international Workshop on New Treatment Strategies in Ankylosing Spondylitis, Berlin, Germany, 18-19 January 2002 / J. Braun, J. Sieper // Ann. Rheum. Dis. — 2002. — Vol.3. — P. 1161-1167.

2. Braun J., Bollow M., Remlinger G., et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. Jan 1998;41(1):58-67.

3. Braun J., Sieper J. Ankylosing spondylitis. Lancet. Apr 21 2007;369(9570):1379-90.

4. Gratacos J., Collado A., Pons F., et al.: Significant loss of bone mass in patients with early, active ankylosing spondylitis. A follow-up study. Arthritis Rheum 1999; 42: 2319-24.

5. Crotti T.N., Smith M.D., Weedon H. et al. Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 2002;61:1047-54.

6. Lange U., Kluge A., Strunk J. Ankylosing spondylitis and bone mineral density — what is the ideal tool for measurement. Rheumatol Int 2005; 26: 115-20.

7. Bessant R., Keat A. (2002) How should clinicians manage osteoporosis in ankylosing spondylitis? J Rheumatol 29, 1511-9.

8. Meireless E.S., Borelli A., Camargo O.P. Influence of disease activity and chronicity on ankylosing spondylitis bone mass loss. clin Rheumatol 1999;18:364-8.

9. Sinigaglia L., Varenna M., Girasole G., Bianchi G. Epidemiology of osteoporosis in rheumatic diseases. Rheum Dis Clin North Am 2006; 32:631-658.

10. Ulusoy H., Bilgici A., Kuru O. et al. Relationship between bone mineral density and disease activity in patients with ankylosing spondylitis. Turk J Rheumatol 2010; 25: 24-8.

11. Donnelly S., Doyle D.V., Denton A., Rolfe I., McCloskey E.V., Spector T.D. Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis 1994; 53: 117-21.

12. Lee Y.S., Schlotzhauer T., Ott S.M., van Vollenhoven R.F., Hunter J., Shapiro J., et al. Skeletal status of men with early and late ankylosing spondylitis. Am J Med 1997; 103: 203-41.

13. Ralston SH, Urquhart GDK, Brzeski M et al. Prevalence of vertebral compression fracture due to osteoporosis in ankylosing spondylitis. Br Med J 1990; 300:563-565.

14. Braun J., Pincus T. — Mortality, course and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol 2002; 20:S16-S22.

15. Jun J.B., Joo K.B., Her M.Y., et al. Femoral bone mineral density is associated with vertebral fractures in patients with ankylosing spondylitis: a cross-sectional study. J Rheumatol 2006; 33:1637-1641.

16. Maksymovych W.P., Jhangri G.S., Leclercq S., Skeith K., Yan A, Russell AS. An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol 1998; 25: 714-7.

17. Allali F., Breban M., Procher R., Maillefert J.F., Dougados M., Roux C. Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor. Ann Rheum Dis 2003; 63: 347-9.

18. J. Sieper, M. Rudwaleit, X. Baraliakos et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009; 68(Suppl II):ii1-ii44.

19. The world Health Organization (2007) Assessment of osteoporosis at the primary health care level — Summary report of a WHO Scientific Group. WHO, Geneva.

20. Binkley N., Bilezikian J.P., Kendler D.L., et al. (2007) Summary of the international society for clinical densitometry 2005 position development conference. J Bone Miner Res 22, 643.

21. El. Maghraoui, Borderie D., Cherruau B., Edouard R., Dougados M., Roux C. Osteoporosis, body composition, and bone turnover in ankylosing spondylitis. J Rheumatol 1999; 26: 2205-9.

22. Speden D.J., Calin A.I., Ring F.J., Bhalla A.K. Bone mineral density, calcaneal ultrasound, and bone turnover markers in women with ankylosing spondylitis. J Rheumatol 2002; 29: 516-21.

23. Capaci K., Hepguler S., Argin M., et al — Bone mineral density in mild and advanced ankylosing spondylitis. Yonsei Med J 2003; 44:379-384.

24. Mitra D., Elvins D.M., Speden D.J., et al — The prevalence of vertebral fractures in mild ankylosing spondylitis and their relationship to bone mineral density. Rheumatology 2000; 39:85-89.

25. Toussirot E., Michel F., Wendling D. — Bone density, ultrasound measurements and body composition in early ankylosing spondylitis. Rheumatology 2001; 40: 882-888.

26. Wendling D. — Bone loss in ankylosing spondylitis: Can we put the puzzle together? J Rheumatol 2005; 32:1184-1186.

27. Dos Santos FP, Constantin A, Laroche M, et al — Whole body and regional bone mineral density in ankylosing spondylitis. J Rheumatol 2001; 28:547-549.

28. Maillefert JF, Aho LS, El Maghraoui A, et al — Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. Osteoporos Int 2001; 12:605-609.

29. Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J, van der Linden S, van der Heijde D. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:18-24.


Review

For citations:


MYaSOUTOVA L.I., LAPShINA S.A., SALIKhOV I.G., VASIL'EV A.G. IZMENENIYa MINERAL'NOY PLOTNOSTI KOSTNOY TKANI U BOL'NYKh ANKILOZIRUYuShchIM SPONDILOARTRITOM. Osteoporosis and Bone Diseases. 2011;14(3):14-18. (In Russ.) https://doi.org/10.14341/osteo2011314-18

Views: 402


ISSN 2072-2680 (Print)
ISSN 2311-0716 (Online)